{"id":"ipratropium-levosalbutamol-free-dose-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1621597","moleculeType":"Small molecule","molecularWeight":"332.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ipratropium blocks muscarinic acetylcholine receptors on airway smooth muscle, preventing bronchoconstriction, while levosalbutamol (the active R-enantiomer of albuterol) stimulates beta-2 adrenergic receptors to promote bronchodilation. Together, they provide rapid and sustained airway opening through dual mechanisms, commonly used in acute and chronic obstructive airway disease management.","oneSentence":"This combination uses an anticholinergic bronchodilator (ipratropium) and a short-acting beta-2 agonist (levosalbutamol) to relax airway smooth muscle through complementary pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:02.337Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm in chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma exacerbation"},{"name":"Reversible airway obstruction"}]},"trialDetails":[{"nctId":"NCT06040424","phase":"PHASE3","title":"Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2023-09-28","conditions":"COPD","enrollment":74},{"nctId":"NCT05890638","phase":"PHASE3","title":"Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2023-08-25","conditions":"COPD","enrollment":74},{"nctId":"NCT04446637","phase":"PHASE3","title":"Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD","status":"WITHDRAWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2021-09-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ipratropium + Levosalbutamol Free Dose Combination","genericName":"Ipratropium + Levosalbutamol Free Dose Combination","companyName":"Neutec Ar-Ge San ve Tic A.Ş","companyId":"neutec-ar-ge-san-ve-tic-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses an anticholinergic bronchodilator (ipratropium) and a short-acting beta-2 agonist (levosalbutamol) to relax airway smooth muscle through complementary pathways. Used for Acute bronchospasm in chronic obstructive pulmonary disease (COPD), Asthma exacerbation, Reversible airway obstruction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}